A robust VZV-specific cell-mediated immunity is required to prevent herpes zoster (51), thus we used ELISPOT assay to evaluate the induction of gE-specific splenocytes secreting IFN-γ or IL-2 by all vaccine candidates two weeks after boost immunization. This evidence concerns the gene IL2 and herpes zoster.